Gagandeep Singh, F.A.C.S., M.D.

Dr. Singh is an internationally recognized liver and pancreas surgeon. He is the Chief of the Hepatobiliary and Pancreatic Surgery Program at City of Hope, a National Cancer Institute-designated Comprehensive Cancer Center. He is also the Director of the Neuroendocrine Tumor Program and is the Lead for the GI Disease Team.

 

He started his faculty academic career at the Keck School of Medicine at University of Southern California (USC) in Los Angeles. From there, he was appointed as the Director of the Liver and Pancreas Center at the John Wayne Cancer Institute, Santa Monica, CA, where he also served as Chair of the Cancer Committee, and Vice President for Fellowship Education.  In 2010, City of Hope asked Dr. Singh to spearhead the liver and pancreatic cancer program. He was appointed Clinical Professor of Surgery and as the new Chief of the Division of Surgical Oncology and hoisted the program to national recognition. He has an extensive referral base that reflects peer recognition of his clinical acumen and surgical expertise and is listed in “America’s Top Surgeons”, “Best Doctors of America”, “Super Doctors” and “Top Doctors of America.”

 

Prior to his tenure in the Unites States, he earned is his Medical Degree from the Mahatma Gandhi Institute of Medical Sciences, India, and then trained at some of the finest cancer centers and hepatobiliary institutes across the world. These international institutions include: Tata Memorial Hospital and Cancer Center (Bombay, India), René Descartes University - Hôpital Cochin (Paris, France), and the Royal Liverpool University Hospital (UK- England). In the USA, these institutes include: Marion Bessin Liver Center at Albert Einstein College of Medicine (New York), Maricopa Medical Center (Phoenix), and the University of Iowa Hospitals & Clinics (Iowa City). Dr. Singh is a board-certified surgeon, a Diplomate of the American Board of Surgery and a Fellow of the American College of Surgeons. He is a member of some of the top elite surgical societies and has served as invited speaker/chair at several national and international conferences. He is also a panel member of the National Comprehensive Cancer Network (NCCN) for Hepatobiliary Cancers, that lays down the guidelines for the standard of care for these cancers; providing direction to both patients and physicians across the USA and the rest of the world.

 

Dr. Singh has a very thoughtful, effective and yet forceful approach to beating cancer, in a systematic fashion working with an outstanding multi-disciplinary team. Dynamic and compassionate, he is a skilled and an accomplished surgeon. He has extensive experience in liver and pancreatic diseases and other gastrointestinal cancers. His work is very well published with numerous publications in prestigious journals. His publications encompass complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions following difficult pancreatic surgery for pancreatic cancer, and advanced robotic surgery. Currently, his group is advancing the scope and providing cutting edge surgery for complex liver and pancreatic operations using minimally invasive surgery (MIS) techniques with the 3D high-definition da Vinci robotic surgical systems. His work in robotic surgery has been presented on the national podium at the Society of Surgical Oncology (SSO), Americas Hepato-Pancreato-Biliary Association (AHPBA) and other national meetings.

 

An innovator at heart, Dr. Singh is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborative endeavors with engineers from California Institute of Technology (Caltech) & Harvey Mudd College. He has several invention disclosures and patents.

 

In addition to a large clinical practice, Dr. Singh is passionately advancing cutting-edge translational research. He collaborates with City of Hope’s molecular biologists, X-ray crystallographers, structural chemists and super-resolution scientists. A visionary clinician who is developing novel targeted molecules for neuroendocrine tumors, pancreatic cancers and metastatic colon and rectal cancers. He believes, early detection is critical, and is authenticating an early detection blood test for pancreatic cancers and colorectal cancers.

 

 

JOURNAL OF CLINICAL PATHWAYS

LACNETS

 

PANCREATIC CANCER ACTION NETWORK